News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promising Durability Data Presented for BioVentrix’s Novel Heart Failure Treatment


10/10/2013 6:51:42 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the presentation of scientific data demonstrating the durability of its Revivent™ Myocardial Anchoring System in 24 patients one year post-procedure. These data, presented this week at the prestigious European Association for Cardio-Thoracic Surgery meeting in Vienna, Austria, by Dr. Andrew Wechsler, professor of cardiothoracic surgery at Drexel University (Philadelphia, Penn., USA), highlighted results from the Company’s Phase I clinical trial conducted at five European centers.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES